A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib

Jaime L Schneider; Alona Muzikansky; Jessica J Lin; Elizabeth A Krueger; Inga T Lennes; Joseph O Jacobson; Michael Cheng; Rebecca S Heist; Zofia Piotrowska; Justin F Gainor; Alice T Shaw; Ibiay Dagogo-Jack

doi:10.1016/j.jtocrr.2022.100347

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib

JTO Clin Res Rep. 2022 Jun 8;3(7):100347. doi: 10.1016/j.jtocrr.2022.100347. eCollection 2022 Jul.

Authors

Jaime L Schneider^{1

2}, Alona Muzikansky¹, Jessica J Lin^{1

2}, Elizabeth A Krueger¹, Inga T Lennes^{1

2}, Joseph O Jacobson³, Michael Cheng³, Rebecca S Heist^{1

2}, Zofia Piotrowska^{1

2}, Justin F Gainor^{1

2}, Alice T Shaw^{1

2}, Ibiay Dagogo-Jack^{1

2}

Affiliations

¹ Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts.
³ Dana-Farber Cancer Institute, Boston, Massachusetts.

Abstract

Introduction: The central nervous system (CNS) is a common site of progression among patients with ROS1-rearranged lung cancer receiving crizotinib. We conducted a phase 2 study to evaluate the intracranial efficacy of lorlatinib in patients with ROS1-rearranged lung cancer who developed CNS-only progression on crizotinib.

Methods: Patients with metastatic ROS1-rearranged lung cancer with CNS-only progression on crizotinib received lorlatinib 100 mg daily. The primary end point was intracranial disease control rate at 12 weeks per modified Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included intracranial and extracranial progression-free survival, intracranial objective response rate, and safety/tolerability.

Results: A total of 16 patients were enrolled between November 2016 and January 2019. Nine patients (56%) had received prior CNS radiation, with a median of 10.9 months between radiation and lorlatinib. At 12 weeks, the intracranial disease control rate was 100% and intracranial objective response rate was 87%. While on study, the complee intracranial response rate was 60%. With median follow-up of 22 months, seven patients experienced disease progression, including five patients with CNS relapse. The median intracranial and extracranial progression-free survivals were 38.8 months (95% confidence interval: 16.9-not reported) and 41.1 months (95% confidence interval: 17.6-not reported), respectively. Molecular analysis of plasma or tissue from patients with extracranial progression on lorlatinib revealed ROS1 G2032R (n = 1), ROS1 L2086F (n = 1), and CCDC6-RET fusion plus ROS1 G2032R (n = 1). The safety profile of lorlatinib was consistent with prior studies. There were 11 patients (69%) who required dose reduction, including one patient who discontinued treatment for grade 3 edema. No grade greater than or equal to 4 adverse events were observed.

Conclusions: Lorlatinib induced durable intracranial responses in patients with ROS1-rearranged NSCLC and prior isolated CNS progression on crizotinib.

Keywords: Brain metastasis; Crizotinib; Lorlatinib; Lung cancer; ROS1.